Brought to you by 
Exelixis, PDL develop cancer antibodies; deal concluded
24 May 2006
Executive Summary
In a two-year deal, Exelixis (comparative genomics and model system genetics) will combine its model organism genetics technology with Protein Design Labs' (humanized antibodies to treat autoimmune and inflammatory conditions, asthma, and cancer) clinical expertise to identify and develop antibodies to treat cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Exelixis, PDL develop cancer antibodies; deal concluded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice